19 Jul Astellas Pharma
Erin Kimbrel, Ph.D., Head, Cell and Gene Therapy Research
Oct. 6 | 12:15pm | FLW Ballroom F
Tokyo, Japan
(NASDAQ: ALPMY)
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. Through our R&D programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. This includes our focus on delivering breakthrough gene therapies with life-changing potential for patients across many disease areas. We are building one of the world’s most robust pipelines of gene therapies for genetic disorders and an end-to-end gene therapy infrastructure with industry-leading discovery, development, manufacturing and commercial capabilities. With our partners, we have several candidates in clinical development including for rare neuromuscular diseases: KT430, in partnership with Kate Therapeutics, approaching First Subject Dosed for XLMTM by end of year, and AT845 in Phase 1/2 for Pompe disease. Alongside partners, clinicians, regulatory authorities and patient communities, we strive to overcome complex challenges across the value chain so we can deliver the promise of ground-breaking science to patients.
